MET and gastroesophageal junction adenocarcinoma: Since Lennerz etal has demonstrated that 2% of patients (10/489) with esophagogastric adenocarcinoma, who harbored MET amplification and were treated with a MET inhibitor, experienced tumor shrinkage in 2011 [12], MET gene status has gained considerable interest in solid tumors [13, 14].